44results about How to "Inhibit autophagy" patented technology

The invention discloses a cell autophagy inhibitor taking rubiaceae-type cyclopeptides as effective components. The cell autophagy inhibitor is particularly used for inhibiting KRAS mutation, particularly KRAS dependent tumor cell protective autophagy, and promoting tumor cell apoptosis. The inhibitor is preferably a nano-micelle injection and can be applied to preparation of medicines for treating and preventing KRAS related cancers such as colon cancers, rectal cancers, lung cancers and pancreatic cancers. The cell autophagy inhibitor can effectively inhibit tumor cell protective autophagy, the rubiaceae-type cyclopeptides serving as the effective components are wide in source, the extraction process is mature, dosage forms and pharmacy modes are diversified, and the inhibitor can be applied to treatment and prevention of the KRAS related cancers and has a wide clinical application prospect.

The invention provides application of a DNA tetrahedron to induction of autophagy. The DNA tetrahedron is synthesized from four single DNA strands through self-assembling, wherein the sequences of thefour single DNA strands are shown in SEQ ID No. 1-4. The DNA tetrahedron can activate a PI3K / AKT / mTOR signaling pathway so as to conduct induction effect on autophagy. Specifically, the DNA tetrahedron can act on the upstream protein AKT of mTOR and conducts inhibition effect on the expression of the protein mTOR by activating the expression of AKT; meanwhile, DNA tetrahedron can negatively act on mTOR by up-regulating the expression of the upstream protein PI3K of mTOR so as to allow the expression of mTOR to be inhibited, so autophagy is further induced and biomolecules in cells are highlyrecycled for the cells, and thus, the proliferation and migration of cells are improved.

The invention discloses an application of ligustilide as an adjuvant drug of antitumor drugs. The research found that ligustilide can directly inhibit autophagy and then can perform combined effects with the antitumor drugs such as tamoxifen, cis-platinum and the like, the antitumor effect is improved, and the drug resistance of tumor cells to the antitumor drugs can be improved.

The present invention provides a pharmaceutical composition for treating digestive tract cancers, belongs to the technical field of drugs and an application of FTY720 or a combination of the FTY720 with JTE-013 in preparation of 5-fluorouracil (5-FU) drug resistance reversal agents. The provided pharmaceutical composition for treating the digestive tract cancers comprises 5-fluorouracil and at least one of the following 5-fluorouracil drug resistance reversal agents: FTY720 and JTE-013. The present invention also provides use of SphK2 and S1PR2 in screening drugs for reversing drug resistanceof fluorouracil compounds for the digestive tract cancers. The SphK2 up-regulates DPD expression-induced fluorouracil primary drug resistance and S1PR2 translocation-induced fluorouracil acquired drugresistance, and besides, the SphK2 and S1PR2 can be used as new molecular targets by designing targeted drugs to solve a drug resistance problem of the fluorouracil and derivatives thereof in cancertreatment processes.

The invention provides application of brown algae oligosaccharide or pharmaceutically acceptable salt thereof in preparation of a medicine for treating acute kidney injury, wherein the brown algae oligosaccharide is brown algae disaccharide, brown algae triose and / or brown algae tetraose. The invention also provides application of the brown algae oligosaccharide or the pharmaceutically acceptable salt thereof in preparation of medicines for preventing acute kidney injury from being converted into chronic kidney diseases. After the brown algae oligosaccharide is used for treating an animal with acute kidney injury, the serum creatinine level is obviously reduced, the urine concentration function of the kidney is obviously recovered, the levels of renal tubular injury factors (KIM-1 and NGAL) are obviously reduced, the expression of inflammatory factors is obviously reduced, the pathological change of the kidney is obviously improved, and the treatment effect is enhanced along with the increase of the dosage. Therefore, the brown algae oligosaccharide disclosed by the invention has a relatively strong effect of treating the acute kidney injury. In addition, when acute kidney injury occurs, the brown algae oligosaccharide disclosed by the invention can be used for protecting kidney functions and preventing the acute kidney injury from being converted into chronic kidney diseases.

The invention provides a combined medicine for treating malignant tumors. The combined medicine contains unit preparations with different specifications and is used for simultaneously or respectivelysupplying genetically engineered bacteria and chloroquine diphosphate salt. The combined medicine disclosed by the invention can be used for effectively treating cancers, and the effect is obviously superior to that of single use of the genetically engineered bacteria and the chloroquine diphosphate salt, so that the genetically engineered bacteria and the chloroquine diphosphate salt have an obvious synergistic effect after cooperating for use, have strong anti-tumor activity and small side effects, and provide a new treatment direction for patients who lose operation indications clinically,cannot be operated and have poor radiotherapy and chemotherapy effects.

A method for inhibiting the autophagy of motor neurons in a subject is provided. The method comprises administrating to the subject an effective amount of an active ingredient selected from the group consisting of a compound of formula (I), a pharmaceutically acceptable salt of the compound, a pharmaceutically acceptable ester of the compound and combinations thereof:wherein A is a C1-C5 alkyl optionally having one or more unsaturated bonds and optionally being substituted by one or more substituents selected from a group consisting of —OH, ═O and C1-C3 alkyl; X is H, —OH,Y is O or S and can optionally combine with A to form a five-membered ring; and R1 is H or a substituted or unsubstituted C1-C20 alkyl, wherein one or more —CH2— of the C1-C20 alkyl are optionally being replaced by —NH— or —O—.

Provided herein are recombinant peptides useful for inhibiting the function of autophagy-related 8 (Atg8) proteins. The recombinant peptides can be used in the preparation of imaging agents for monitoring autophagy in a cell or subject and treating autophagy related diseases, such as cancer.

The invention discloses a cell autophagy inhibitor with Rubiaceae type cyclic peptide as an active ingredient, especially for inhibiting KRAS mutation, especially KRAS-dependent tumor cell protective autophagy, and promoting tumor cell apoptosis; The inhibitor is preferably a nano-micelle injection, which can be applied to the preparation of drugs for treating and preventing KRAS-related cancers, including colon cancer, rectal cancer, lung cancer and pancreatic cancer. The autophagy inhibitor described in the present invention can effectively inhibit the protective autophagy of tumor cells. Its active ingredient Rubiaceae type cyclic peptide has a wide range of sources, its extraction process is mature, and its dosage forms and medication methods are diversified. It can be applied to the treatment of KRAS-related cancers. Treatment and prevention have broad clinical application prospects.

The invention discloses an application of ligustilide as an adjuvant drug of antitumor drugs. The research found that ligustilide can directly inhibit autophagy and then can perform combined effects with the antitumor drugs such as tamoxifen, cis-platinum and the like, the antitumor effect is improved, and the drug resistance of tumor cells to the antitumor drugs can be improved.

The invention relates to a medical configuration item, and particularly relates to a chronic cyclosporin A nephrotoxicity prevention and treatment pharmaceutical composition, the pharmaceutical composition comprises an effective component and a pharmaceutical acceptable auxiliary material, the effective component is an aqueous extract prepared from the following medicinal raw materials by weight: 26-30% of fructus rosae laevigatae, 20-25% of emblic leafflower fruit, 12-15% of fruit of Chinese magnoliavine and 30-40% of gynostemma pentaphylla. The chronic cyclosporin A nephrotoxicity prevention and treatment pharmaceutical composition has remarkable effect on chronic cyclosporin A nephrotoxicity prevention and treatment.

The present invention discloses new uses of 3,4-fragmented cyclic altine-type triterpenoids, the compounds are black schisandrin or southern schisandra, including for preparing autophagy inhibitor, preparing for increasing antitumor drug treatment A sensitive drug, the compound can inhibit the ubiquitination modification of autophagy receptor p62, prevent the activation of p62 autophagy receptor function, and can inhibit the protective autophagy of tumor cells induced by anti-tumor drugs, and the present invention also provides An anti-tumor drug composition, including 3,4-fragmented cyclic altine-type triterpenoids and anti-tumor drugs that easily induce tumor cell protective autophagy, can inhibit tumor cell growth and promote tumor cell death, and can be used for Treatment of cancers such as breast cancer.

The invention provides new application for a lycorine and bortezomib composition medicine. The lycorine and bortezomib composition is used for preparing a medicinal preparation for treating multiple myeloma. Compared with the fact that lycorine and bortezomib are used separately, combined use of lycorine and bortezomib can realize a better cell proliferation inhibition effect, and cell autophagy can be inhibited through combined use. The composition greatly improves sensibility of multiple myeloma to bortezomib and is applicable to drug-resistant multiple myeloma which is difficult to treat.

The invention discloses an application of seneciphylline in preparation of antitumor medicines. The seneciphylline can inhibit HeLa cell proliferation and induce HeLa cell autophagy in a dose dependent and a time dependent manner. In addition, the seneciphylline inducing the HeLa cell autophagy is depended on activation of MEK / ERK1 / 2 pathway. The invention provides a novel treatment medicine of treating human cervical cancer.